Patents Assigned to Medical College of Georgia Research Institute
-
Patent number: 6773890Abstract: It has been determined that a specific metaplastic lineage that contains immunoreactivity for a trefoil polypeptide, spasmolytic peptide, is associated with and gives rise to the vast majority of human adenocarcinomas. The identification of this Spasmolytic Polypeptide Expressing Metaplasia (SPEM) is a major factor for grading of biopsies of the stomach to assess risk for gastric cancer. It also forms the basis of a method for serological screening for those at risk for gastric cancer. In a preferred embodiment, antibodies to spasmolytic peptide (hSP) are used in immunostaining of biopsies of gastric tissue obtained by endoscopy for grading biopsies. Those patients having these cells, characterized by a morphology more typical of a type of cell present normally in the intestine and not stomach, Brunner's gland cells, are at risk of developing adenocarcinoma.Type: GrantFiled: January 29, 2002Date of Patent: August 10, 2004Assignee: Medical College of Georgia Research Institute, Inc.Inventors: James R. Goldenring, P. Henry Schmidt, Jeffrey R. Lee
-
Publication number: 20040147475Abstract: Introduction of double stranded RNA into cells, cell culture, organs and tissue, and whole organisms, particularly vertebrates, specifically attenuates gene expression.Type: ApplicationFiled: February 5, 2004Publication date: July 29, 2004Applicant: Medical College of Georgia Research Institute, Inc.Inventors: Yin-Xiong Li, Michael J. Farrell, Margaret J. Kirby
-
Publication number: 20020178461Abstract: Disclosed are transgenic fish, and a method of making transgenic fish, which express transgenes in stable and predictable tissue- or developmentally-specific patterns. The transgenic fish contain transgene constructs with homologous expression sequences. Also disclosed are methods of using such transgenic fish. Such expression of transgenes allow the study of developmental processes, the relationship of cell lineages, the assessment of the effect of specific genes and compounds on the development or maintenance of specific tissues or cell lineages, and the maintenance of lines of fish bearing mutant genes.Type: ApplicationFiled: April 30, 2002Publication date: November 28, 2002Applicant: Medical College of Georgia Research Institute, Inc.Inventor: Shuo Lin
-
Patent number: 6482416Abstract: A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and therefore other types of transplantation, and that inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HIV. Inhibiting tryptophan degradation (and thereby increasing tryptophan concentration while decreasing tryptophan metabolite concentration), or supplementing tryptophan concentration, can therefore be used in addition to, or in place of, inhibitors of IDO.Type: GrantFiled: November 30, 2000Date of Patent: November 19, 2002Assignee: Medical College of Georgia Research Institute, Inc.Inventors: David Munn, Andrew Mellor
-
Publication number: 20020155104Abstract: A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and therefore other types of transplantation, and that inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HIV. Inhibiting tryptophan degradation (and thereby increasing tryptophan concentration while decreasing tryptophan metabolite concentration), or supplementing tryptophan concentration, can therefore be used in addition to, or in place of, inhibitors of IDO.Type: ApplicationFiled: March 28, 2002Publication date: October 24, 2002Applicant: Medical College of Georgia Research Institute, Inc.Inventors: David Munn, Andrew Mellor
-
Patent number: 6469141Abstract: A number of cDNA clones whose products may interact with D1 receptors in vivo were identified. One of the clones, P24, was characterized further. P24 is localized in dendrites and spines of pyramidal cells in PFC. The extent of overlap between P24 expressing and D1 receptor expressing pyramidal cells appeared to be 100%. In contrast, only a limited number D1 receptor antibody labeled neurons in caudate expressed P24. P24 lowers the threshold of D1 receptor response to dopamine (DA) by an order of magnitude. Sequence similarity suggests P24 is a diverged member of the RAMP family. The P24 protein is therefore referred to as a D1 DA RAMP, calcyon. The isolated protein and nucleotide molecule encoding the protein, as well as primers for the nucleotide, are described. The protein and compounds modifying DA binding to the receptor or calcium release which is mediated by the Calcyon, are useful in research studies, drug screening, and therapeutically.Type: GrantFiled: October 8, 1999Date of Patent: October 22, 2002Assignee: Medical College of Georgia Research Institute Inc.Inventor: Clare Bergson
-
Patent number: 6451840Abstract: A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and therefore other types of transplantation, and that inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HIV. Inhibiting tryptophan degradation (and thereby increasing tryptophan concentration while decreasing tryptophan metabolite concentration), or supplementing tryptophan concentration, can therefore be used in addition to, or in place of, inhibitors of IDO.Type: GrantFiled: December 4, 1998Date of Patent: September 17, 2002Assignee: Medical College of Georgia Research Institute, Inc.Inventors: David Munn, Andrew Mellor
-
Patent number: 6441158Abstract: Disclosed are oligomers that bind Ku protein. These oligomers are useful for inhibiting activation of DNA-PK, treating certain forms of autoimmune disease, detection and purification of Ku protein, and identification of proteins that interact with Ku protein. Preferably, the oligomers are composed of nucleotides, nucleotide analogs, or a combination. Most preferably, the oligomers are composed of ribonucleotides. Also disclosed is a method of inhibiting DNA repair, a method of identifying cellular proteins that interact with Ku protein, and a method of treating autoimmune disease in patients with anti-Ku antibodies. The disclosed oligomers can have several preferred features, either alone or in combination, in addition to Ku binding. One such feature, referred to herein as inhibition activity, is inhibition of DNA-PK kinase activity. Another preferred feature, referred to herein as aptamer motifs, is the presence of one or more of the base sequences GCUUUCCCANNNAC, A(A/C)AUGA, and AACUUCGA.Type: GrantFiled: December 30, 1998Date of Patent: August 27, 2002Assignee: Medical College of Georgia Research Institute, Inc.Inventors: William S. Dynan, Sunghan Yoo
-
Publication number: 20020114784Abstract: Introduction of double stranded RNA into cells, cell culture, organs and tissues, and whole organisms, particularly vertebrates, specifically attenuates gene expression.Type: ApplicationFiled: January 4, 2002Publication date: August 22, 2002Applicant: Medical College of Georgia Research Institute, Inc.Inventors: Yin-Xiong Li, Michael J. Farrell, Margaret L. Kirby
-
Patent number: 6395876Abstract: A high affinity and extremely selective tryptophan transport system present in human monocyte-derived macrophages is disclosed. Human monocyte-derived macrophages include two distinct transporters, a high affinity (Km=290±160 nM) transporter that is highly specific for tryptophan and a low affinity (Km=27±4 &mgr;M) transporter that is less specific for tryptophan, consistent with the known system L. The tryptophan transport system is predominantly (86%) sodium-independent. The high-affinity system is very specific for tryptophan and shows no transport of any other essential amino acids in the tryptophan transport concentration range. This high-affinity system is expressed at very low levels in fresh monocytes, but undergoes a 10-30 fold induction during macrophage differentiation.Type: GrantFiled: December 4, 1998Date of Patent: May 28, 2002Assignee: Medical College of Georgia Research Institute, Inc.Inventors: David Munn, Andrew Mellor
-
Patent number: 6395549Abstract: Disclosed are an enhancer, insulator, and promoter from the HS5 region in the 5′ boundary area of the locus control region of human &bgr;-like globin genes. These transcription control sequences can be used to control expression of any desired gene of interest and can be used in any vector for this purpose. The control sequences are derived from the area in and around the U3 region of a solitary endogenous retrovirus (ERV) 9 long terminal repeat (LTR). Also disclosed are methods of expressing any gene of interest. For this purpose, the control sequences can be operably linked to the gene of interest (and operably linked to each other). The disclosed enhancers, insulators, and promoters can also be used with any other control sequences. Preferably, the control sequences are used in vectors to obtain expression of a gene of interest in a cell, including cells in animals.Type: GrantFiled: October 21, 1999Date of Patent: May 28, 2002Assignee: Medical College of Georgia Research Institute, Inc.Inventors: Dorothy Tuan, Qiaoming Long, Chikh Bengra
-
Patent number: 6391281Abstract: A method of topically applying a fluorescing agent to a cut tooth, cut dental restorative material or dentin surface to distinguish between cut tooth or dentin and existing aesthetic restoration material or enamel specifically for the purposes of detection and identification of the tooth tissue dentin.Type: GrantFiled: May 18, 2000Date of Patent: May 21, 2002Assignee: Medical College of Georgia Research InstituteInventors: Fred Rueggeberg, Don Mettenberg, John Wataha, Frank Caughman, George Schuster
-
Patent number: 6380458Abstract: Disclosed are transgenic fish, and a method of making transgenic fish, which express transgenes in stable and predictable tissue- or developmentally-specific patterns. The transgenic fish contain transgene constructs with homologous expression sequences. Also disclosed are methods of using such transgenic fish. Such expression of transgenes allow the study of developmental processes, the relationship of cell lineages, the assessment of the effect of specific genes and compounds on the development or maintenance of specific tissues or cell lineages, and the maintenance of lines of fish bearing mutant genes.Type: GrantFiled: June 9, 1997Date of Patent: April 30, 2002Assignee: Medical College of Georgia Research Institute, Inc.Inventor: Shuo Lin
-
Publication number: 20010001040Abstract: A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and therefore other types of transplantation, and that inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HIV. Inhibiting tryptophan degradation (and thereby increasing tryptophan concentration while decreasing tryptophan metabolite concentration), or supplementing tryptophan concentration, can therefore be used in addition to, or in place of, inhibitors of IDO.Type: ApplicationFiled: November 30, 2000Publication date: May 10, 2001Applicant: Medical College of Georgia Research Institute, Inc.Inventors: David Munn, Andrew Mellor
-
Patent number: 6107048Abstract: A method of detecting dysplastic regions within epithelial tissue samples is sensitive enough to detect and distinguish between low grade and high grade dysplastic regions. The method uses probes specific for expression and accumulation of substances within a particular intracellular region from a defect in apical membrane trafficking (trafficking markers) and in the preferred embodiment correlates the trafficking marker levels with the presence of an oncogene such as p53. If low grade dysplasia is present, trafficking markers are detected in a distinctive perinuclear pattern. Previous studies have demonstrated a high correlation of p53 over-expression with high grade dysplasia and adenocarcinoma. Detection of p53 is shown to be mutually exclusive of detection of trafficking markers. Therefore, dual detection for both the trafficking markers and p53 provides an accurate method for more precise grading of biopsies.Type: GrantFiled: November 20, 1997Date of Patent: August 22, 2000Assignee: Medical College of Georgia Research Institute, Inc.Inventors: James R. Goldenring, Gregory S. Ray, Jeffrey R. Lee
-
Patent number: 6096303Abstract: It has been discovered that cells such as genetically engineered fibroblasts and keratinocytes can be cultured in the cyst fluid of encapsulated tumors. This provides a means for proliferating genetically engineered producer cells within these types of tumors, increasing the number of cells producing viral particles, which then transduce the surrounding tumor cells with the genetic material, in the preferred embodiment, a lethal gene. A number of different tumor types form "cysts", which contain fluid produced by the tumor cells, including brain tumor cells such as gliomas, and many types of breast, and lung tumors. These cyst fluids have been shown to contain elevated levels of certain growth factors, for example, fibroblast growth factor (FGF) and epidermal growth factor (EGF).Type: GrantFiled: July 31, 1997Date of Patent: August 1, 2000Assignee: Medical College of Georgia Research Institute, Inc.Inventor: James R. Fick
-
Patent number: 5488954Abstract: An improved ultrasonic transducer fabricated on a silicon base has a piezoelectric layer of polyvinylidene fluoride-trfluroethylene copolymer. The piezoelectric layer is sandwiched between two conductive electrodes, all of which are supported on a dielectric layer on top of the silicon base. At least one of the electrodes forms a Fresnel zone plate to focus the ultrasonic signals from the transducers. To improve the performance of the transducer, the silicon base behind the active area is removed, leaving the dielectric layer as a membrane to support the electrodes and the piezoelectric layer. The resulting void in the silicon base is filled with an acoustically matched backing, such as an epoxy, to enhance the wideband performance of the transducer. The transducer is especially suited for characterizing anatomical structures or features requiring very high resolution.Type: GrantFiled: September 9, 1994Date of Patent: February 6, 1996Assignees: Georgia Tech Research Corp., Medical College of Georgia Research InstituteInventors: Michael Z. Sleva, William D. Hunt, David M. Connuck, Ronald D. Briggs
-
Patent number: 4792520Abstract: A new and improved cell assay has been developed for mutagens and potential carcinogens to precisely identify the predominant type of mutation(s) each such compound induces in the DNA of cells. The test utilizes, for example, a selectable genetic marker such as adenine phosphoribosyltransferase (APRT) which is now extensively characterized on the DNA, protein and cellular phenotype levels. Specific mutations such as transitions, transversions, point insertions or point deletions are engineered at specific known sites in a mouse APRT gene deduced from the determined gene sequence, such that the gene cannot be properly expressed. These mutant genes are then introduced into non-reverting APRT deficient mammalian cells. These hybrid constructs represent the basic test medium for detection of mutagenic activity. The tester cells are treated with mutagens known to preferentially induce specific DNA mutations in mammalian cells.Type: GrantFiled: February 16, 1984Date of Patent: December 20, 1988Assignees: University of Cincinnati, Medical College of Georgia Research InstituteInventors: Peter J. Stambrook, Jay A. Tischfield